Semaglutide Program in Seattle
US$ 28.82
tirzepatide for ckd (Zepbound) showed improved kidney function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https Effects of Renal Impairment on
Description
But raw percentages can be misleading without understanding the trial designs, patient populations, and timelines involved
Tirzepatide/Mounjaro already has FDA approval for diabetes, and it now has two global phase 3 clinical trials supporting its potential for weight loss, following even stronger SURMOUNT-1 results among non-diabetic patients (up to 22% weight loss)
The C-terminus is amidated, further enhancing its resistance to degradation
ZEPBOUNDTM (tirzepatide) Injection, for subcutaneous use
doi: 10.1016/j.bone.2017.06.010 [DOI] [PMC free article] [PubMed] [Google Scholar] 40
